TKT and graft versus host disease: Two suicide genes have been validated in the clinic for control of GVHD from administration of donor T cells after HSCT in an effort to enhance immune recovery and maximize graft-vs.-leukemia (GVL) effect: the iCasp9 and the HSV-TK suicide genes.